ImpediMed Limited
ImpediMed Limited (IPDQF) Revenue
Annual & quarterly revenue history · segment & region breakdown
IPDQF · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsImpediMed Limited trailing twelve-month (TTM) revenue is $0.03B, an increase of 26.57% year-over-year from $0.01B in FY2025.
Revenue trend
2025 – 2008 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-06-30 | $0.01B | +$0.00B | +26.57% |
| 2024-06-30 | $0.01B | -$0.00B | -11.38% |
| 2023-06-30 | $0.01B | +$0.00B | +8.09% |
| 2022-06-30 | $0.01B | +$0.00B | +25.64% |
| 2021-06-30 | $0.01B | +$0.00B | +46.70% |
| 2020-06-30 | $0.01B | +$0.00B | +38.95% |
| 2019-06-30 | $0.00B | -$0.00B | -14.57% |
| 2018-06-30 | $0.00B | -$0.00B | -16.81% |
| 2017-06-30 | $0.01B | -$0.00B | -0.43% |
| 2016-06-30 | $0.01B | +$0.00B | +19.55% |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income ImpediMed Limited receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
ImpediMed Limited reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in AUD.
Data sourced from ImpediMed Limited's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
IPDQF revenue · 4 questionsIPDQF's trailing twelve-month (TTM) revenue is $0.03B. That is an increase of 26.57% year-over-year from $0.01B in FY2025.
▸ Source: FMP · ImpediMed Limited SEC filings · GAAP · ImpediMed Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026